A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Affiliations

• ¹ ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy alessandra.tedeschi@ospedaleniguarda.it.
• ² Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria.
• ³ Dokuz Eylul University, Izmir, Turkey.
• ⁴ Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
• ⁵ Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
• ⁶ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
• ⁷ Tennessee Oncology, Chattanooga, TN, USA.
• ⁸ North Shore Hospital, Auckland, New Zealand.
• ⁹ Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
• ¹⁰ Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• ¹¹ Norton Cancer Institute, Louisville, KY, USA.
• ¹² Princess Alexandra Hospital, Brisbane, Australia.
• ¹³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
• ¹⁴ University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
• ¹⁵ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁶ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
• ¹⁷ Janssen Ltd, High Wycombe, UK.
• ¹⁸ Barts Cancer Institute, Queen Mary University of London, London, UK.